Rheumatoid Arthritis

Detailed Overview

RA affects small joints of the hands and feet first, producing significant pain, swelling, and prolonged morning stiffness. The hallmark is the formation of a 'pannus'—hypertrophied, inflamed synovial tissue that invades and destroys adjacent cartilage and bone. Beyond the joints, systemic inflammation accelerates atherosclerosis, drastically increasing cardiovascular mortality. Early, aggressive use of Disease-Modifying Antirheumatic Drugs (DMARDs) within the 'window of opportunity' is critical to halt joint destruction.

Epidemiology & Demographics

Prevalence is approximately 0.5-1% of the adult population globally. It is 2-3 times more common in women than in men. Peak onset is between ages 30 and 50 in women, and slightly later in men.

Etiological Mechanism

Arises from a loss of immunologic tolerance to self-antigens. It requires a genetic predisposition (HLA-DRB1 alleles containing the 'Shared Epitope') combined with environmental triggers, most notably cigarette smoking, which induces citrullination of proteins in the lungs.

Primary Causes

Primary cause is autoimmune CD4+ T-cell and B-cell activation against citrullinated proteins (anti-CCP). Environmental triggers (smoking, periodontitis via Porphyromonas gingivalis, viral infections like EBV) trigger mucosal inflammation that breaks immune tolerance in genetically susceptible hosts.

• Genetics: Presence of the HLA-DRB1 'shared epitope' accounts for the majority of genetic risk.
• Smoking: The strongest environmental risk factor; it promotes the conversion of arginine to citrulline in mucosal surfaces.
• Sex: Female sex hormones (estrogen) may enhance immune responses, explaining the 3:1 female-to-male ratio.
• Periodontal Disease: Porphyromonas gingivalis produces an enzyme that citrullinates human proteins.

Environmental insults cause citrullination of proteins (e.g., vimentin, type II collagen). Antigen-presenting cells display these to CD4+ T cells. T cells activate B cells to produce autoantibodies (Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide). Immune complexes deposit in the synovium, activating complement. Macrophages and T cells in the synovium secrete abundant pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6). This drives synovial fibroblasts and macrophages to proliferate, forming a thickened, hyperplastic pannus. The pannus secretes matrix metalloproteinases (MMPs) that degrade cartilage, and RANK-ligand, which hyperactivates osteoclasts to cause periarticular bone erosions.

Characteristic Clinical Presentation

• Symmetric Joint Pain: Dull, aching pain affecting the same joints on both sides of the body (e.g., both wrists, both knees).
• Morning Stiffness: Severe stiffness in affected joints lasting >1 hour after waking, improving with movement.
• Constitutional Symptoms: Low-grade fever, fatigue, malaise, and unintentional weight loss during disease flares.

Physical Examination Signs

• Joint Swelling
• Ulnar Deviation
• Rheumatoid Nodules

• Cervical Spine Instability: Atlantoaxial (C1-C2) subluxation due to erosion of the transverse ligament; risks spinal cord compression.
• Interstitial Lung Disease (ILD): Fibrotic lung disease presenting as chronic dry cough and progressive dyspnea.
• Cardiovascular Disease: Accelerated atherosclerosis causing premature MI and stroke, the leading cause of death in RA.

Diagnostic Criteria & Guidelines

Diagnosed using the 2010 ACR/EULAR classification criteria. Requires a score >= 6/10 based on: number of small joints involved, positive serology (RF and anti-CCP), elevated acute phase reactants (CRP, ESR), and symptom duration >= 6 weeks.

Differential Diagnosis

• Osteoarthritis (affects DIPs, brief morning stiffness <30 mins)
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Parvovirus B19 infection (acute symmetric polyarthritis)
• Gout or Pseudogout

Laboratory Tests & Biomarkers

• Anti-CCP (ACPA): Positive in 70-80% of patients. Highly specific (95%) and predicts a more aggressive, erosive disease course.
• Rheumatoid Factor (RF): Positive in 70-80%. Less specific than anti-CCP (found in aging, Hep C, endocarditis).
• CRP and ESR: Significantly elevated, correlating with current disease activity.

Imaging Modalities & Findings

• X-ray (Hands/Feet): Early: soft tissue swelling and periarticular osteopenia. Late: marginal bone erosions, uniform joint space narrowing, and subluxations.
• Ultrasound/MRI: Highly sensitive for detecting early synovitis, tenosynovitis, and bone marrow edema before X-ray changes occur.

• Early RA
  Symptoms < 6 months. Synovial inflammation present, but X-rays show no bone erosions yet. The optimal time to start DMARDs.
• Established RA
  Symptoms > 6 months. Active inflammation. X-rays show joint space narrowing and periarticular osteopenia/erosions.
• Late/End-stage RA
  Fibrous or bony ankylosis (fusion) of joints, extensive deformities (Boutonniere, Swan-neck), loss of function.

Second-Line & Adjunctive Therapy

If target (remission or low disease activity) is not reached with MTX, add a Biologic DMARD (bDMARD). Options include TNF-alpha inhibitors (Adalimumab 40 mg SC every 2 weeks, Etanercept 50 mg SC weekly) or IL-6 inhibitors (Tocilizumab). Alternatively, Targeted Synthetic DMARDs (tsDMARD) like JAK inhibitors (Upadacitinib 15 mg PO daily).

Surgical & Procedural Management

Synovectomy for isolated resistant joints. Tendon transfer or repair for ruptured tendons. Total joint arthroplasty (knee/hip replacement) for end-stage destroyed joints to restore mobility and relieve pain.

Recommended Lifestyle Changes

• Absolute smoking cessation, as continued smoking severely blunts the efficacy of DMARDs, especially MTX and TNF-inhibitors.
• Cardiovascular exercise and physical therapy to maintain joint range of motion and prevent muscle atrophy.
• Mediterranean diet rich in omega-3 fatty acids may provide modest symptomatic relief.

Patient Counseling & Advice

Stress that RA medications (DMARDs) take weeks to months to work; they must not stop taking them just because they don't feel immediate pain relief. Advise on infection risks associated with biologics. Prior to any surgery with intubation, a cervical spine X-ray is mandatory to check for C1-C2 instability.

Follow-Up & Monitoring Schedule

Treat-to-target strategy: Assess disease activity using scores like DAS28 or CDAI every 1-3 months. For Methotrexate: monitor CBC, CMP (liver enzymes), and serum creatinine every 2-3 months. Screen for TB (Quantiferon-Gold) and Hepatitis B/C prior to starting any biologic.

Preventive Strategies

No absolute prevention, but avoiding smoking and maintaining good dental hygiene (preventing periodontitis) are the strongest modifiable factors for those with a family history.

With early aggressive DMARD therapy, clinical remission is achievable in 40-50% of patients, preventing severe deformities. However, without treatment, 50% of patients will have work disability within 10 years. Life expectancy is reduced by 3-10 years primarily due to cardiovascular disease.